Markets
← Back to Stocks
MRK
MERCK + CO. INC.
Health Care · Pharmaceuticals
$114.17
-0.29%
Vol: 0.1M
Araverus Market Read
Thursday, March 19, 2026
Long-term vaccine efficacy data and new Phase 3 trial announcements reinforce Merck pipeline strength
Merck announced new long-term data showing GARDASIL 9 and GARDASIL HPV vaccines remain effective for at least 14-18 years, and announced late-breaking data from three Phase 3 trials for Doravirine/Islatravir at CROI 2026. MRK is trading at $115.33 in pre-market, down 0.24%, with after-hours at $114.50, down 0.81% from yesterday's close. The company continues to advance its pipeline with positive clinical data.
Price 50d 200d
Previous Market Reads
2 of 2 daysSector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $916.83 | -0.13% | -11.4% | 21.8x | 0.43 | $821.2B |
| JNJJOHNSON | $237.56 | +0.16% | -1.8% | 18.9x | 0.33 | $572.6B |
| ABBVABBVIE | $206.31 | -0.97% | -11.4% | 12.8x | 0.33 | $364.6B |
| MRKMERCK | $114.17 | -0.29% | -5.4% | 11.7x | 0.26 | $282.3B |
| UNHUNITEDHEALTH | $280.37 | -1.29% | -2.2% | 14.1x | 0.38 | $254.5B |
| AMGNAMGEN | $349.90 | -0.42% | -6.3% | 15.0x | 0.42 | $188.6B |
| ABTABBOTT | $107.19 | -1.12% | -4.5% | 17.2x | 0.74 | $186.3B |
| GILDGILEAD | $141.06 | -0.17% | -8.6% | 14.7x | 0.37 | $175.2B |
| TMOTHERMO | $470.21 | +1.18% | -6.2% | 17.5x | 0.97 | $174.7B |
Fundamentals
Market Cap$282.3B
P/E (TTM)15.7
Forward P/E11.7
Beta0.26
Div Yield297.00%
Prev Close$114.50
RSI (14-Day)
20Oversold
0305070100
52-Week Range
$73.31$114.17$125.14
From High-8.8%
From Low+55.7%
Moving Averages
50d SMA
$114.76-0.5%
200d SMA
$92.97+22.8%
Price between 50d and 200d. Testing 50d support.
Returns
1W
-0.8%
1M
-5.5%
3M
+17.0%
6M
+43.0%
1Y
+24.9%
YTD
+8.0%
Volume
Today141K
20d Avg9.5M
Ratio0.01x